Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MBX-102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MBX-102 200 mg | EXPERIMENTAL | MBX-102 200 mg once daily for 16 weeks |
| MBX-102 400 mg | EXPERIMENTAL | MBX-102 400 mg once daily for 16 weeks |
| MBX-102 600 mg | EXPERIMENTAL | MBX-102 600 mg once daily for 16 weeks |
| Sugar Pill | PLACEBO_COMPARATOR | Placebo comparator once daily for 16 weeks |
| Actos | ACTIVE_COMPARATOR | Actos 30 mg once daily for 16 weeks |
| Name | Type | Description |
|---|---|---|
| MBX-102 | DRUG | MBX-102 200 mg once daily for 16 weeks |
| Placebo | DRUG | MBX-102 Placebo once daily for 16 weeks |
| Actos | DRUG | Actos 30 mg once daily for 16 weeks |
Inclusion Criteria: * Type 2 diabetes (as described by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus24) treated with insulin alone (a stable dose of long and/or intermediate-acting insulin or pre-mixed insulin e.g., "70/30") ≥ 30 units/day for at least 3 months, but ...
Top 20 of 31 competitors
MBX-102 is a small molecule being developed for the treatment of Type 2 Diabetes. It is currently in Phase 2 clinical development and is being studied in patients whose blood sugar is not adequately controlled with insulin therapy.
The specific molecular target of MBX-102 has not been disclosed. It is a small molecule therapeutic being developed for Type 2 Diabetes, but its mechanism of action is not publicly detailed in the available information.
MBX-102 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes.
MBX-102 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it is not yet approved by regulatory authorities. The drug remains investigational and is being studied for its potential use in Type 2 Diabetes.
MBX-102 has one completed clinical trial, identified as NCT00353587. This was a Phase 2, randomized, double-blind, placebo-controlled study that enrolled 396 participants with Type 2 Diabetes who were suboptimally controlled on insulin. The trial was conducted in the United States, Argentina, India, and Israel.
Yes, MBX-102 is also known as Metaglidasen. The clinical trial NCT00353587, which evaluated the drug in Type 2 Diabetes, refers to it as Metaglidasen. Both names refer to the same investigational small molecule being developed by Gilead Sciences.